Teva Pharmaceutical Industries is a globally operating Israeli multinational headquartered in Petah Tikva. As the world’s largest generic drug producer, Teva maintains manufacturing facilities across Israel, including in illegal West Bank settlements, and exports medications worldwide. The company benefits from Israel’s occupation economy by leveraging captive Palestinian markets and providing tax revenue to the state, while also suppressing local Palestinian pharmaceutical competition.
Teva has been hit with major legal penalties,including a US$450 million DOJ settlement in 2024 over kickbacks and price-fixing for generic drugs. The company has faced allegations of labor discrimination, including age bias and workplace culture complaints in the United States. Despite public ESG reporting, including supplier assessments across 3,500 vendors, Teva continues to draw criticism for enabling apartheid infrastructure through its deep integration into the Israeli state economy.
Teva is rated High Impact because of its foundational role in Israel’s apartheid economy and its global pharmaceutical influence. By operating within settlements and supplying medications in occupied territories, Teva materially underpins colonial control and limits Palestinian access to affordable healthcare. Its financial contributions, via taxes and market monopolization, strengthen the occupation infrastructure. The company has also been implicated in systemic corporate harm through antitrust violations, price-fixing instruments, and a hostile labor environment. The combination of political complicity, corporate malfeasance, and public health dominance makes Teva a strategically critical boycott target for both Palestinian solidarity activists and global justice movements.